MCID: CNG021
MIFTS: 54

Congenital Toxoplasmosis

Categories: Blood diseases, Fetal diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Congenital Toxoplasmosis

MalaCards integrated aliases for Congenital Toxoplasmosis:

Name: Congenital Toxoplasmosis 12 74 52 58 15 17 32
Toxoplasmosis, Congenital 74 43 71
Mother-to-Child Transmission of Toxoplasmosis 52 58
Toxoplasma Embryofetopathy 52 58
Toxoplasma Embryopathy 52 58
Toxoplasmosis Congenital 54
Toxoplasmosis - Congen. 12

Characteristics:

Orphanet epidemiological data:

58
congenital toxoplasmosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe),1-5/10000 (United States); Age of onset: Adolescent,Adult,Antenatal,Childhood,Infancy,Neonatal;

Classifications:

Orphanet: 58  
Rare neurological diseases
Developmental anomalies during embryogenesis
Teratologic disorders
Rare infectious diseases


Summaries for Congenital Toxoplasmosis

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 858 Definition Congenital toxoplasmosis (CTX) is an embryo-fetopathy characterized by ocular, visceral or intracranial lesions secondary to maternal primo-infection by Toxoplasma gondii (Tg). Epidemiology Given its infectious origin, incidence of CTX is variable over time and geographically. Screening policies and methods also influence prevalence calculation. A low estimate of the overall prevalence might be of 1:3,030 births, with symptomatic cases at 1:29,000 births. Clinical description Clinical presentation is highly variable. Earlier infection is generally more severe but less frequent. Infections in the first trimester may result in miscarriage or fetal death in utero , whereas later ones may be limited to ocular anomalies. Intracranial calcifications, micro- or macrocephaly, ventricular dilatation and hydrocephalus , hepatomegaly, splenomegaly, cardiomegaly, ascites and intrauterine growth retardation can be observed in infected fetuses. When present, clinical manifestations at birth are maculopapular rash, jaundice , generalized lymphadenopathy, organomegaly, central nervous system anomalies and hyperbilirubinemia, anemia , and thrombocytopenia . The first neurologic manifestation is seizures ; nystagmus , hypotonia and, later, delay of developmental milestones acquisition can be seen. The chorioretinitis - intracranial calcifications - hydrocephalus triad is present in 10% of cases. Ocular involvement may develop after months or years, most frequently with chorioretinitis, followed by microphthalmia and strabismus . Visual impairment is highly dependent on the parasite genotype , and probably on prenatal and postnatal treatments. Etiology CTX is caused by the mother's primo-infection by Tg, an intracellular protozoan parasite of the Apicomplexa phylum, and transmission to the fetus by trans-placental infection. Nearly 25% of exposed fetuses are infected. Mother is infected by Tg through ingestion of ooccysts present in cat faeces and soil, or of cysts present in uncooked meat. Diagnostic methods Diagnosis relies on evidence of infection in the fetus, the infant or the child with a history of maternal primo-infection during pregnancy or up to 6 months before conception. Given the poor specificity of clinical signs observed in Tg infection, serological findings and PCR amplification of Tg specific sequences are the main diagnostic clues. RT-PCR targeting repetitive DNA segments was reported to be more sensitive and not less specific than previous tests. Differential diagnosis Differential diagnosis includes other congenital infections (rubella, CMV, HSV1 and HSV2, regrouped with Tg infection in the TORCH syndrome ) and pseudo-TORCH and Aicardi-Goutieres syndromes (see these terms). Antenatal diagnosis Fetal ultrasonography and/or magnetic resonance imaging (MRI) detect and characterize brain, cardiac or placental anomalies. Diagnosis is confirmed only with serological or PCR findings of Tg infection in the mother and the amniotic fluid. Amniocentesis should be performed at least 4 weeks after the mother's seroconversion to avoid false negative results due to latency. Management and treatment In several countries, a systematic serological status follow-up of each pregnant woman is organized in order to diagnose and treat early maternal and fetal infections. Seronegative pregnant women are tested regularly to detect seroconversion, with, if needed, a spiramycin-based treatment, expected to reduce vertical transmission. A pyrimethamine-sulphonamide combination is recommended in case of confirmed fetal infection. Neonates should also be treated even if they are asymptomatic at birth since complications may occur later. The benefits of prenatal and postnatal treatment remain to be assessed. Prognosis Prognosis is highly dependent on the parasite genotype, the gestational age at maternal infection and on the timing of prenatal and postnatal treatment. Visit the Orphanet disease page for more resources.

MalaCards based summary : Congenital Toxoplasmosis, also known as toxoplasmosis, congenital, is related to toxoplasmosis and ocular toxoplasmosis. An important gene associated with Congenital Toxoplasmosis is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Allograft rejection and NF-kappaB Signaling. The drugs leucovorin and Spiramycin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and eye, and related phenotypes are abnormality of retinal pigmentation and premature birth

Disease Ontology : 12 A toxoplasmosis that involves a reactivated infection of the mother transmitted to the fetus during pregnancy. Spontaneous abortion and stillbirth may occur.

Wikipedia : 74 Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii. Infections with toxoplasmosis usually... more...

Related Diseases for Congenital Toxoplasmosis

Diseases in the Toxoplasmosis family:

Congenital Toxoplasmosis

Diseases related to Congenital Toxoplasmosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 432)
# Related Disease Score Top Affiliating Genes
1 toxoplasmosis 31.6 NLRP1 IL10 HLA-DQB1 HLA-DQA1 DHFR CD79A
2 ocular toxoplasmosis 31.3 CD79A CD40LG
3 neuroretinitis 30.6 CD40LG CD4
4 congenital syphilis 30.1 CD79A CD40LG CD4
5 chorioretinitis 29.9 IL10 DHFR CD8A CD40LG CD4
6 choroiditis 29.9 IL10 CD40LG CD4
7 syphilis 29.8 CD8A CD79A CD40LG CD4
8 good syndrome 29.7 CD8A CD40LG CD4
9 pancytopenia 29.5 DHFR CD8A CD40LG CD4
10 otitis media 29.4 IL10 CD79A CD40LG
11 histoplasmosis 29.4 HLA-DQA1 CD8A CD40LG CD4
12 immune deficiency disease 29.4 IL10 CD79A CD40LG CD4
13 acquired immunodeficiency syndrome 29.3 IL10 CD79A CD40LG CD4
14 rubella 29.2 IL10 HLA-DQB1 HLA-DQA1 CD40LG
15 exanthem 29.0 IL10 CD8A CD40LG CD4
16 lupus erythematosus 29.0 NLRP1 IL10 HLA-DQB1 HLA-DQA1 CD40LG
17 listeriosis 29.0 IL10 CD8A CD4
18 keratitis, hereditary 28.9 IL10 CD8A CD4
19 salmonellosis 28.9 IL10 CD8A CD4
20 chickenpox 28.8 IL10 CD8A CD40LG CD4
21 meningoencephalitis 28.8 IL10 CD8A CD79A CD40LG CD4
22 eye disease 28.7 IL10 COL2A1 CD8A CD40LG CD4 ABCA4
23 hemorrhagic fever-renal syndrome 10.6 CD79A CD40LG
24 c1q nephropathy 10.6 CD79A CD40LG
25 hydrocephalus 10.6
26 hilar lung carcinoma 10.6 CD79A CD40LG
27 lung hilum cancer 10.6 CD79A CD40LG
28 immunoglobulin g deficiency 10.6 CD79A CD40LG
29 cryofibrinogenemia 10.6 CD79A CD40LG
30 monoclonal paraproteinemia 10.5 CD79A CD40LG
31 achalasia, familial esophageal 10.5 HLA-DQB1 HLA-DQA1
32 primary adrenal insufficiency 10.5 HLA-DQB1 HLA-DQA1
33 beryllium disease 10.5 HLA-DQB1 HLA-DQA1
34 plasmodium malariae malaria 10.5 DHFR CD40LG
35 focal epithelial hyperplasia 10.4 HLA-DQB1 HLA-DQA1
36 riedel's fibrosing thyroiditis 10.4 CD40LG CD4
37 podoconiosis 10.4 HLA-DQB1 HLA-DQA1
38 interval angle-closure glaucoma 10.4 HLA-DQA1 ABCA4
39 latent syphilis 10.4 CD40LG CD4
40 gastroduodenitis 10.4 CD40LG CD4
41 primary syphilis 10.4 CD40LG CD4
42 asymptomatic neurosyphilis 10.4 CD40LG CD4
43 tertiary neurosyphilis 10.4 CD40LG CD4
44 transient arthritis 10.4 CD40LG CD4
45 meningovascular neurosyphilis 10.4 CD40LG CD4
46 optic papillitis 10.4 CD40LG CD4
47 immunodeficiency with hyper-igm, type 1 10.4 CD79A CD40LG
48 viral exanthem 10.4 CD40LG CD4
49 gastrointestinal tuberculosis 10.4 CD40LG CD4
50 idiopathic bronchiectasis 10.4 HLA-DQB1 HLA-DQA1

Graphical network of the top 20 diseases related to Congenital Toxoplasmosis:



Diseases related to Congenital Toxoplasmosis

Symptoms & Phenotypes for Congenital Toxoplasmosis

Human phenotypes related to Congenital Toxoplasmosis:

58 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of retinal pigmentation 58 31 hallmark (90%) Very frequent (99-80%) HP:0007703
2 premature birth 58 31 hallmark (90%) Very frequent (99-80%) HP:0001622
3 hydrocephalus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000238
4 nystagmus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000639
5 seizures 58 31 occasional (7.5%) Occasional (29-5%) HP:0001250
6 muscular hypotonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001252
7 cerebral calcification 58 31 occasional (7.5%) Occasional (29-5%) HP:0002514
8 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
9 global developmental delay 58 31 occasional (7.5%) Occasional (29-5%) HP:0001263
10 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
11 intrauterine growth retardation 58 31 occasional (7.5%) Occasional (29-5%) HP:0001511
12 microcephaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0000252
13 visual impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000505
14 cognitive impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0100543
15 cardiomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001640
16 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
17 anemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001903
18 macule 58 31 occasional (7.5%) Occasional (29-5%) HP:0012733
19 failure to thrive in infancy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001531
20 elevated hepatic transaminase 58 31 occasional (7.5%) Occasional (29-5%) HP:0002910
21 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
22 jaundice 58 31 occasional (7.5%) Occasional (29-5%) HP:0000952
23 ventriculomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002119
24 microphthalmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000568
25 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
26 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716

MGI Mouse Phenotypes related to Congenital Toxoplasmosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 ABCA4 BAG1 CD4 CD40LG CD79A CD8A
2 immune system MP:0005387 9.4 ABCA4 CD4 CD40LG CD79A CD8A COL2A1

Drugs & Therapeutics for Congenital Toxoplasmosis

Drugs for Congenital Toxoplasmosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4 58-05-9 6006 143
2
Spiramycin Approved Phase 4 24916-50-5
3
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
4
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
5
Levoleucovorin Approved, Investigational Phase 4 68538-85-2
6
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
7
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
8 Anti-Bacterial Agents Phase 4
9 Folic Acid Antagonists Phase 4
10 Hormones Phase 4
11 Vitamins Phase 4
12 Vitamin B Complex Phase 4
13 Vitamin B9 Phase 4
14 Trace Elements Phase 4
15 Micronutrients Phase 4
16 Protective Agents Phase 4
17 Folate Phase 4
18 Nutrients Phase 4
19 Calcium, Dietary Phase 4
20 Antidotes Phase 4
21 Anti-Infective Agents Phase 4
22 Antimalarials Phase 4
23 Antiparasitic Agents Phase 4
24 Antiprotozoal Agents Phase 4
25 Pharmaceutical Solutions

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis Recruiting NCT00004317 Phase 4 Leucovorin calcium;Pyrimethamine;Spiramycin;Sulfadiazine
2 Multicentre, Randomised Study to Determine the Relative Efficacy of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis Unknown status NCT01202500 Phase 3
3 Multicenter, Randomized Clinical Trial to Compare the Efficacy and Tolerance of Prenatal Therapy With Pyrimethamine + Sulfadiazine vs Spiramycine to Reduce Vertical Transmission of Toxoplasma Gondii Following Primary Infection in Pregnancy Completed NCT01189448 Phase 3 Pyrimethamine/Sulfadiazine;Spiramycine
4 Lyon Clinical Research Program on Maternal and Congenital Toxoplasmosis Based on the Toxo-Ly Cohort: Risks and Clinical Consequences, Prevention, Diagnosis and Treatment Recruiting NCT02936921
5 TOXODIAG: New Diagnostic Approach for Congenital Toxoplasmosis Recruiting NCT03385499
6 Protocol Study for a Randomized Controlled Trial of the Effects of Transcranial Direct Current Stimulation (tDCS) Associated With Proprioceptive Training in Blind People Not yet recruiting NCT03173105

Search NIH Clinical Center for Congenital Toxoplasmosis

Cochrane evidence based reviews: toxoplasmosis, congenital

Genetic Tests for Congenital Toxoplasmosis

Anatomical Context for Congenital Toxoplasmosis

MalaCards organs/tissues related to Congenital Toxoplasmosis:

40
Testes, Brain, Eye, Lymph Node, Placenta, T Cells, Skin

Publications for Congenital Toxoplasmosis

Articles related to Congenital Toxoplasmosis:

(show top 50) (show all 1853)
# Title Authors PMID Year
1
Recovery of anti-Toxoplasma gondii immunoglobulin M in stored guthrie card blood spots. 54 61
19494076 2009
2
Comparative immunoglobulin G antibody profiles between mother and child (CGMC test) for early diagnosis of congenital toxoplasmosis. 61 54
11015373 2000
3
Three children with congenital toxoplasmosis: early report from a Swedish prospective screening study. 54 61
10419255 1999
4
Detection of Toxoplasma gondii in 94 placentae from infected women by polymerase chain reaction, in vivo, and in vitro cultures. 61 54
9778129 1998
5
Early neonatal diagnosis of congenital toxoplasmosis: value of comparative enzyme-linked immunofiltration assay immunological profiles and anti-Toxoplasma gondii immunoglobulin M (IgM) or IgA immunocapture and implications for postnatal therapeutic strategies. 54 61
8904418 1996
6
Immunoglobulin-A detection and the investigation of clinical toxoplasmosis. 61 54
8474118 1993
7
Platelia-Toxo IgA, a new kit for early diagnosis of congenital toxoplasmosis by detection of anti-P30 immunoglobulin A antibodies. 54 61
1939586 1991
8
Seasonality of births in horizontal strabismus: comparison with birth seasonality in schizophrenia and other disease conditions. 61
30898179 2019
9
Adjunctive bradyzoite-directed therapy for reducing complications of congenital toxoplasmosis. 61
31472369 2019
10
Stability of extemporaneous sulfadiazine oral suspensions from commercially available tablets for treatment of Congenital Toxoplasmosis. 61
31802579 2019
11
Development of an in vitro system to study the developmental stages of Toxoplasma gondii using a genetically modified strain expressing markers for tachyzoites and bradyzoites. 61
31728720 2019
12
Effect of congenital toxoplasmosis on the encoding of speech in infants. 61
31726372 2019
13
Burden of Disease Estimates of Seven Pathogens Commonly Transmitted Through Foods in Denmark, 2017. 61
31755845 2019
14
Ventricular arrhythmia as the first manifestation of congenital toxoplasmosis. 61
31492450 2019
15
Congenital toxoplasmosis as one phenocopy of North Carolina Macular Dystrophy (NCMD/MCDR1). 61
31367689 2019
16
Effects of Congenital Ocular Toxoplasmosis on Peripheral Retinal Vascular Development in Premature Infants at Low Risk for Retinopathy of Prematurity 61
31486615 2019
17
Outcomes of hydrocephalus secondary to congenital toxoplasmosis. 61
31491752 2019
18
Retrospective Evaluation of the Seropositivity Rate of Toxoplasmosis and Clinical Results in Pregnant Women That were Admitted to a Tertiary Health Institution Between 2012 and 2017 in Turkey 61
31502771 2019
19
Follow-up of Toxoplasmosis during Pregnancy: Ten-Year Experience in a University Hospital in Southern Brazil. 61
31546277 2019
20
A review on toxoplasmosis in humans and animals from Egypt. 61
31559938 2019
21
A review of toxoplasmosis in humans and animals in Turkey. 61
31554526 2019
22
Incidence of toxoplasmosis in pregnancy in Campania: A population-based study on screening, treatment, and outcome. 61
31404785 2019
23
Current Situation of Congenital Toxoplasmosis in Ecuador. 61
31456120 2019
24
Toxoplasma Screening Results of 84587 Pregnant Women in a Tertiary Referral Center in Turkey. 61
30912697 2019
25
Multimodal Imaging and Functional Testing in a North Carolina Macular Disease Family: Toxoplasmosis, Fovea Plana, and Torpedo Maculopathy Are Phenocopies. 61
31043363 2019
26
Study of brainstem auditory evoked potentials in early diagnosis of congenital toxoplasmosis. 61
29929810 2019
27
Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil. 61
31077733 2019
28
Toxoplasmosis in Germany. 61
31423982 2019
29
Detection and genotypic characterization of Toxoplasma gondii DNA within the milk of Mongolian livestock. 61
30982139 2019
30
Risk of congenital toxoplasmosis in women with low or indeterminate anti-Toxoplasma IgG avidity index in the first trimester of pregnancy: an observational retrospective study. 61
30315959 2019
31
Detection of Toxoplasma gondii in Cord Blood Samples from Neonates in Tehran, Iran. 61
31523648 2019
32
Susceptibility of human villous (BeWo) and extravillous (HTR-8/SVneo) trophoblast cells to Toxoplasma gondii infection is modulated by intracellular iron availability. 61
30796516 2019
33
Congenital toxoplasmosis: the challenge of early diagnosis of a complex and neglected disease. 61
30994797 2019
34
Sero-epidemiological status and risk factors of toxoplasmosis in pregnant women in Northern Vietnam. 61
30999869 2019
35
Resveratrol as a Therapy to Restore Neurogliogenesis of Neural Progenitor Cells Infected by Toxoplasma gondii. 61
30027338 2019
36
Congenital toxoplasmosis and proposal of a new classification for the likelihood of primary maternal infection: analysis of 375 cases in Southeast Italy. 61
30835583 2019
37
How does toxoplasmosis affect the maternal-foetal immune interface and pregnancy? 61
30471137 2019
38
Maternal and Congenital Toxoplasmosis: Diagnosis and Treatment Recommendations of a French Multidisciplinary Working Group. 61
30781652 2019
39
Congenital human toxoplasmosis caused by non-clonal Toxoplasma gondii genotypes in Argentina. 61
30304711 2019
40
Potential public health benefits from cat eradications on islands. 61
30763304 2019
41
Interpretation of very low avidity indices acquired with the Liaison XL Toxo IgG avidity assay in dating toxoplasmosis infection. 61
30411219 2019
42
The cost-effectiveness of neonatal versus prenatal screening for congenital toxoplasmosis. 61
31532766 2019
43
Detection of Toxoplasma gondii B1 gene in placenta does not prove congenital toxoplasmosis. 61
30103311 2019
44
Congenital toxoplasmosis among Iranian neonates: a systematic review and meta-analysis. 61
31096746 2019
45
Congenital toxoplasmosis in the United States: clinical and serologic findings in infants born to mothers treated during pregnancy. 61
30838974 2019
46
Case report: North Carolina macular dystrophy misdiagnosed as congenital ocular toxoplasmosis. 61
31814698 2019
47
Prevalence and Risk Factors of Toxoplasma gondii Infection among Pregnant Women in Hormozgan Province, South of Iran. 61
31123482 2019
48
Enzyme-Linked Aptamer Assay (ELAA) for Detection of Toxoplasma ROP18 Protein in Human Serum. 61
31799213 2019
49
QuilA-Adjuvanted T. gondii Lysate Antigens Trigger Robust Antibody and IFN╬│+ T Cell Responses in Pigs Leading to Reduction in Parasite DNA in Tissues Upon Challenge Infection. 61
31620134 2019
50
Brazilian strains of Toxoplasma gondii are controlled by azithromycin and modulate cytokine production in human placental explants. 61
30665403 2019

Variations for Congenital Toxoplasmosis

Expression for Congenital Toxoplasmosis

Search GEO for disease gene expression data for Congenital Toxoplasmosis.

Pathways for Congenital Toxoplasmosis

Pathways related to Congenital Toxoplasmosis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 IL10 HLA-DQB1 HLA-DQA1 CD8A CD40LG CD4
2 12.37 NLRP1 IL10 CD8A CD79A CD40LG
3
Show member pathways
12.29 IL10 HLA-DQB1 HLA-DQA1 CD79A CD40LG CD4
4
Show member pathways
12.21 HLA-DQB1 HLA-DQA1 CD40LG CD4
5
Show member pathways
12.07 IL10 HLA-DQB1 HLA-DQA1 CD40LG
6
Show member pathways
11.77 HLA-DQB1 HLA-DQA1 CD4
7 11.77 IL10 CD8A CD79A CD4
8 11.71 IL10 HLA-DQB1 HLA-DQA1
9 11.62 IL10 CD8A CD4
10 11.62 HLA-DQB1 HLA-DQA1 CD8A CD4
11
Show member pathways
11.57 HLA-DQB1 HLA-DQA1 CD4
12 11.56 IL10 CD8A CD4
13 11.38 IL10 CD40LG CD4
14 11.31 HLA-DQB1 HLA-DQA1 CD8A CD4
15 11.27 HLA-DQB1 HLA-DQA1 CD99 CD8A CD40LG CD4
16 10.84 CD8A CD79A CD40LG CD4

GO Terms for Congenital Toxoplasmosis

Cellular components related to Congenital Toxoplasmosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 P2RX7 HLA-DQA1 CD99 CD8A CD40LG CD4
2 external side of plasma membrane GO:0009897 9.02 P2RX7 CD8A CD79A CD40LG CD4

Biological processes related to Congenital Toxoplasmosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.85 NLRP1 HLA-DQB1 HLA-DQA1 CD8A CD79A CD4
2 regulation of immune response GO:0050776 9.71 COL2A1 CD99 CD8A CD40LG
3 B cell differentiation GO:0030183 9.61 IL10 CD79A CD40LG
4 antigen processing and presentation GO:0019882 9.5 HLA-DQB1 HLA-DQA1 CD8A
5 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.48 HLA-DQB1 HLA-DQA1
6 positive regulation of calcium ion transport into cytosol GO:0010524 9.46 P2RX7 CD4
7 B cell proliferation GO:0042100 9.43 IL10 CD79A CD40LG
8 immune response GO:0006955 9.43 IL10 HLA-DQB1 HLA-DQA1 CD8A CD40LG CD4
9 phospholipid transfer to membrane GO:0006649 9.16 P2RX7 ABCA4
10 cell surface receptor signaling pathway GO:0007166 9.02 P2RX7 CD8A CD79A CD4 BAG1

Molecular functions related to Congenital Toxoplasmosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DQA1
2 MHC class II protein binding GO:0042289 8.62 COL2A1 CD4

Sources for Congenital Toxoplasmosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....